Research programme: anticancer antibody therapeutics - AGY Therapeutics

Drug Profile

Research programme: anticancer antibody therapeutics - AGY Therapeutics

Latest Information Update: 10 Oct 2006

Price : $50

At a glance

  • Originator AGY Therapeutics
  • Class Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Glioblastoma; Solid tumours

Most Recent Events

  • 10 Oct 2006 Discontinued - Preclinical for Solid tumours in USA (unspecified route)
  • 10 Oct 2006 Discontinued - Preclinical for Glioblastoma in USA (unspecified route)
  • 24 Jun 2004 Preclinical trials in Solid tumours in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top